At the time, only 6% of patients with HER2-positive breast cancer received trastuzumab in the public system versus 56% in the private sector.1,24 The more advanced stage at diagnosis, coupled with insufficient access to modern systemic therapies, dooms patients to a worse survival outcome when compared with those with private health coverage. Here, ERBB2 is linked to breast cancer.